Stock Information

• Incyte Corp. stock outperforms competitors on strong trading day
  Thu, Apr 2, 2026 5:06 PM
• Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
  Thu, Apr 2, 2026 11:01 AM
• Adagene Collaborates With Incyte To Evaluate Combination Of Muzastotug And INCA33890 In Patients With Microsatellite Stable Colorectal Cancer With Or Without Liver Metastases
  Thu, Apr 2, 2026 7:04 AM
• 5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
  Wed, Apr 1, 2026 11:05 AM
• Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains
  Tue, Mar 31, 2026 5:08 PM
• Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study
  Mon, Mar 30, 2026 6:59 PM
• A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
  Mon, Mar 30, 2026 9:58 AM
• HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $135 Price Target
  Mon, Mar 30, 2026 6:24 AM
• Reported Saturday, Incyte's Povorcitinib Achieves Up To 57% HiSCR75 And 29% HiSCR100 At Week 54 In Phase 3 STOP-HS Trials, With NDA And MAA Under Regulatory Review
  Mon, Mar 30, 2026 2:49 AM
• Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
  Sat, Mar 28, 2026 7:00 PM

Financial data not available